Evolus, Inc. (EOLS) |
|
8.44 0.19 (2.3%)
|
03-24 16:00 |
|
Open: |
8.2 |
Pre. Close: |
8.25 |
|
High:
|
8.48 |
Low:
|
8.13 |
|
Volume:
|
189,013 |
Market Cap:
|
476(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:25:40 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 10.55 One year: 11.35 |
| Support: |
Support1: 7.92 Support2: 6.59 |
| Resistance: |
Resistance1: 9.03 Resistance2: 9.72 |
| Pivot: |
8.55  |
| Moving Average: |
MA(5): 8.36 MA(20): 8.67
MA(100): 8.37 MA(250): 9.86 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 26.8 %D(3): 27.7 |
| RSI: |
RSI(14): 44 |
| 52-week: |
High: 14.34 Low: 6.51 |
| Average Vol(K): |
3-Month: 552 (K) 10-Days: 405 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EOLS ] has closed above bottom band by 40.9%. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.48 - 8.53 |
8.53 - 8.57 |
|
Low:
|
8.03 - 8.08 |
8.08 - 8.12 |
|
Close:
|
8.37 - 8.44 |
8.44 - 8.51 |
|
Company Description |
|
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California. |
Headline News |
Mon, 13 Mar 2023
Hsbc Holdings PLC Cuts Stake in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Mon, 13 Mar 2023
Analysts Set Expectations for Evolus, Inc.'s Q4 2023 Earnings ... - MarketBeat
Sat, 11 Mar 2023
Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 08 Mar 2023
After-Hours Earnings Report for March 8, 2023 : MDB, DADA, VET ... - Nasdaq
Wed, 08 Mar 2023
Evolus Reports Fourth Quarter and Full Year 2022 Results and ... - Business Wire
Wed, 08 Mar 2023
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
56 (M) |
| Shares Float |
33 (M) |
|
% Held by Insiders
|
24.2 (%) |
|
% Held by Institutions
|
58.1 (%) |
|
Shares Short
|
2,210 (K) |
|
Shares Short P.Month
|
2,220 (K) |
Stock Financials |
|
EPS
|
-1.33 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.33 |
|
Profit Margin (%)
|
-50.1 |
|
Operating Margin (%)
|
-38.8 |
|
Return on Assets (ttm)
|
-16.6 |
|
Return on Equity (ttm)
|
-148.3 |
|
Qtrly Rev. Growth
|
25.8 |
|
Gross Profit (p.s.)
|
1.64 |
|
Sales Per Share
|
2.63 |
|
EBITDA (p.s.)
|
-0.96 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-85 (M) |
|
Levered Free Cash Flow
|
-54 (M) |
Stock Valuations |
|
PE Ratio
|
-6.4 |
|
PEG Ratio
|
-1.3 |
|
Price to Book value
|
25.57 |
|
Price to Sales
|
3.2 |
|
Price to Cash Flow
|
-5.61 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
